Analytical Data
-
基因名
SIRP beta 1/CD172b
- Application
-
别名
CD172-B; CD172b; SIRP-B1; SIRP-beta-1; CD172 antigen-like family member B
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
O00241
-
表达区间
Ser127~Gly356
-
分子量
32kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SIRP beta 1, also known as CD172b, is an immunoglobulin-like receptor primarily expressed in myeloid cells, including macrophages and dendritic cells. It plays a crucial role in regulating immune responses, particularly by modulating the interaction between immune cells and their environment. The SIRP/CD47 signaling axis has garnered significant interest in cancer immunotherapy, as CD47, often overexpressed on tumor cells, acts as a "don't eat me" signal, inhibiting phagocytosis by macrophages. By targeting the SIRP beta 1/CD47 pathway, researchers aim to enhance the ability of the immune system to recognize and eliminate cancer cells. Recent studies have indicated that recombinant forms of SIRP beta 1 can block CD47 signaling, promoting the phagocytosis of tumor cells and potentially improving therapeutic efficacy. Furthermore, understanding the structural and functional properties of SIRP beta 1 is essential for the development of novel immunotherapeutic strategies. Hence, characterizing the recombinant SIRP beta 1/CD172b protein is a pivotal step towards elucidating its mechanisms and reinforcing its role as a target in cancer therapy. Researchers are exploring its interactions with various ligands and its downstream signaling pathways, which may reveal new insights into the modulation of immune responses and the design of more effective treatments for cancers and immune-related diseases.
